LEADER 00962nam2-2200325---450- 001 990009088490403321 005 20091021085948.0 035 $a000908849 035 $aFED01000908849 035 $a(Aleph)000908849FED01 035 $a000908849 100 $a20090909d1949----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ay-------001yy 200 1 $a<>intellettuali e l'organizzazione della cultura$fAntonio Gramsci 210 $aTorino$cEinaudi$d1949 215 $aXV, 208 p.$d23 cm 461 0$1001000704687$12001$aOpere di Antonio Gramsci$v3 676 $a305.552$v19$zita 700 1$aGramsci,$bAntonio$f<1891-1937>$0118233 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990009088490403321 952 $aSDI-2KS 161$bs.i.$fSDI 952 $a335.4 GRA 6 (3)$bBibl. 23.005$fFLFBC 959 $aFLFBC 959 $aSDI 996 $aIntellettuali e l'organizzazione della cultura$991295 997 $aUNINA LEADER 03607nam 2200685 a 450 001 9910455395603321 005 20200520144314.0 010 $a1-282-23924-4 010 $a9786612239243 010 $a0-309-13040-9 035 $a(CKB)1000000000787845 035 $a(EBL)3378500 035 $a(SSID)ssj0000200515 035 $a(PQKBManifestationID)11220485 035 $a(PQKBTitleCode)TC0000200515 035 $a(PQKBWorkID)10220290 035 $a(PQKB)10335407 035 $a(MiAaPQ)EBC3378500 035 $a(Au-PeEL)EBL3378500 035 $a(CaPaEBR)ebr10315882 035 $a(CaONFJC)MIL223924 035 $a(OCoLC)923280394 035 $a(EXLCZ)991000000000787845 100 $a20091008d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMedical isotope production without highly enriched uranium$b[electronic resource] /$fCommittee on Medical Isotope Production Without Highly Enriched Uranium, Nuclear and Radiation Studies Board, Division of Earth and Life Studies, National Research Council of the National Academies 210 $aWashington, D.C. $cNational Academies Press$d2009 215 $a1 online resource (221 p.) 300 $aDescription based upon print version of record. 311 $a0-309-13039-5 320 $aIncludes bibliographical references (p. 163-167). 327 $a""Preface""; ""Acknowledgments""; ""Reviewers""; ""Contents""; ""Summary""; ""1 Background and Study Task""; ""2 Molybdenum-99/Technetium-99m Production and Use""; ""3 Molybdenum-99/Technetium-99m Supply""; ""4 Molybdenum-99/Technetium-99m Supply Reliability""; ""5 Molybdenum-99/Technetium-99m Demand""; ""6 Molybdenum-99/Technetium-99m Production Costs""; ""7 Conversion to LEU-Based Production of Molybdenum-99: Technical Considerations""; ""8 Conversion to LEU-Based Production of Molybdenum-99: Regulatory Considerations"" 327 $a""9 Conversion to LEU-Based Production of Molybdenum-99: General Approaches and Timing""""10 Conversion to LEU-Based Production of Molybdenum-99: Prospects and Feasibility""; ""11 Progress in Eliminating HEU Use""; ""References""; ""Appendix A: Section 630 of the Energy Policy Act of 2005""; ""Appendix B: Biographical Sketches of Committee Members""; ""Appendix C: Presentations and Visits""; ""Appendix D: Alternative Molybdenum-99 Production Processes""; ""Appendix E: Correspondence with Atomic Energy of Canada Limited""; ""Appendix F: Present Value Calculation""; ""Appendix G: Glossary"" 327 $a""Appendix H: Acronyms"" 606 $aUranium$xIsotopes$xTherapeutic use 606 $aHighly enriched uranium$xIsotopes$xTherapeutic use 606 $aMolybdenum$xIsotopes$xTherapeutic use 606 $aTechnetium$xIsotopes$xTherapeutic use 606 $aRadioisotopes$xTherapeutic use 606 $aNuclear medicine$xStandards$zUnited States 608 $aElectronic books. 615 0$aUranium$xIsotopes$xTherapeutic use. 615 0$aHighly enriched uranium$xIsotopes$xTherapeutic use. 615 0$aMolybdenum$xIsotopes$xTherapeutic use. 615 0$aTechnetium$xIsotopes$xTherapeutic use. 615 0$aRadioisotopes$xTherapeutic use. 615 0$aNuclear medicine$xStandards 676 $a546.431 712 02$aNational Research Council (U.S.).$bNuclear and Radiation Studies Board. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910455395603321 996 $aMedical isotope production without highly enriched uranium$92236438 997 $aUNINA LEADER 04026nam 2200589Ia 450 001 9910461952503321 005 20200520144314.0 010 $a3-8428-2289-8 035 $a(CKB)2670000000250570 035 $a(EBL)1035593 035 $a(OCoLC)815391732 035 $a(SSID)ssj0000739726 035 $a(PQKBManifestationID)11384294 035 $a(PQKBTitleCode)TC0000739726 035 $a(PQKBWorkID)10697227 035 $a(PQKB)11203727 035 $a(MiAaPQ)EBC1035593 035 $a(Au-PeEL)EBL1035593 035 $a(CaPaEBR)ebr10596712 035 $a(EXLCZ)992670000000250570 100 $a20120916d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aVariables influencing the severity of IPO underpricing$b[electronic resource] $ean empirical analysis of the German Market /$fJustyna Dietrich 210 $aHamburg $cDiplomica Verlag$d2012 215 $a1 online resource (76 p.) 300 $aDescription based upon print version of record. 311 $a3-8428-7289-5 320 $aIncludes bibliographical references. 327 $aVariables Influencing the Severity of IPO Underpricing: An Empirical Analysis of the German Market; Acknowledgements; Table of Content; List of Figures; List of Tables; List of Appendices; List of Abbreviations; List of Symbols; 1 Introduction; 2 Theoretical Aspects of an IPO; 2.1 Definition of an IPO; 2.2 The IPO Price Setting Process; 2.2.1 Business Valuation; 2.2.2 Share Pricing; 2.3 The Special Role of the Underwriter in the IPO Process; 3 IPO Underpricing; 3.1 Definition of IPO Underpricing and Empirical Evidence; 3.2 The Winner's Curse Hypothesis; 3.3 Market Feedback Hypothesis 327 $a3.4 Bandwagon Hypothesis3.5 Lawsuit Avoidance; 3.6 Signalling; 3.7 Investment Banker's Monopsony Power; 3.8 Principal Agent Problem; 3.9 Prospect Theory; 3.10 Anchoring; 4 Long-Run Performance and Overvaluation of IPOs; 4.1 Evidence on Initial Investor Overoptimism; 4.2 Reasons for Initial Overvaluation; 4.2.1 Overreaction Hypothesis; 4.2.2 Representativeness Heuristic; 4.2.3 Divergence of Opinion Hypothesis; 4.2.4 Big Winner Hypothesis; 4.2.5 Underwriter Conflict of Interest; 4.2.6 Window-Dressing; 5 Empirical Analysis of Underpricing in Germany; 5.1 Development of Explanatory Variables 327 $a5.1.1 Management Ownership5.1.2 Pre-Market Demand; 5.1.3 Recent Market Movements; 5.1.4 Underwriter Reputation; 5.1.5 Industry, Company Age and Firm Size; 5.2 Theoretical Model and Statistical Method; 5.3 Data and Descriptive Statistics; 5.4 Results and Interpretation; 5.4.1 Management Ownership; 5.4.2 Pre-Market Demand; 5.4.3 Recent Market Movements; 5.4.4 Underwriter Reputation; 5.4.5 Industry, Company Age and Firm Size; 6 Conclusion; Bibliography; List of Online Sources and Software; Appendix; Autorenprofil 330 $aHauptbeschreibung Underpricing refers to the phenomenon of abnormal first-day returns from initial public offerings (IPOs). Without doubt, any US investor would agree that one day-returns of 11.4% on average are exceptional and a worthwhile investment. Since then many studies have proven that it is a persistent phenomenon and also occurs on markets all over the world. The most puzzling question for scientists is why companies are leaving this money on the table and do not set an offering price that reflects the market demand at the offering date. The main focus of this pape 606 $aGoing public (Securities) 606 $aStocks$xPrices$zGermany 606 $aSecurities$xListing$zGermany 608 $aElectronic books. 615 0$aGoing public (Securities) 615 0$aStocks$xPrices 615 0$aSecurities$xListing 676 $a382.0947 700 $aDietrich$b Justyna$0869848 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910461952503321 996 $aVariables influencing the severity of IPO underpricing$91942145 997 $aUNINA